Aug 13, 2025 12:00
KLRS - Kalaris Therapeutics, Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 5.12 -0.38 (-7.42%) | --- | --- | --- | --- | -0.19 (-3.76%) | -0.24 (-4.73%) | -0.24 (-4.73%) |
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- -2.52
- Diluted EPS:
- -2.52
- Basic P/E:
- -1.881
- Diluted P/E:
- -1.881
- RSI(14) 1m:
- 0.0
- VWAP:
- 4.74
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|